Zoetis Inc. $ZTS Stock Position Decreased by J. Stern & Co. LLP

Key Points

• J. Stern & Co. LLP reduced its stake in Zoetis Inc. by 2.1%, holding 209,186 shares valued at approximately $34.4 million. This makes Zoetis the firm's 17th largest position.
• Additional hedge funds have increased their positions in Zoetis, with Tandem Investment Advisors Inc. growing its holdings by over 100% in the same quarter.
• Zoetis reported $1.76 earnings per share for the last quarter, surpassing estimates and indicating a revenue increase of 4.2% compared to the previous year.

J. Stern & Co. LLP lowered its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 2.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 209,186 shares of the company's stock after selling 4,524 shares during the quarter. Zoetis accounts for about 3.3% of J. Stern & Co. LLP's investment portfolio, making the stock its 17th largest position. J. Stern & Co. LLP's holdings in Zoetis were worth $34,442,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Portside Wealth Group LLC grew its holdings in Zoetis by 24.7% in the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after buying an additional 6,672 shares during the last quarter. Tandem Investment Advisors Inc. grew its holdings in Zoetis by 100.3% in the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after buying an additional 198,089 shares during the last quarter. Flagship Harbor Advisors LLC grew its holdings in Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after buying an additional 1,760 shares during the last quarter. Horizon Financial Services LLC acquired a new stake in Zoetis in the 1st quarter valued at approximately $380,000. Finally, Sage Rhino Capital LLC grew its holdings in Zoetis by 117.6% in the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock valued at $1,155,000 after buying an additional 3,791 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Down 1.0%

Shares of ZTS opened at $155.1040 on Tuesday. The stock has a fifty day moving average price of $153.66 and a two-hundred day moving average price of $158.30. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a market cap of $68.74 billion, a price-to-earnings ratio of 26.70, a PEG ratio of 2.51 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the previous year, the company posted $1.56 EPS. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.18% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. UBS Group cut their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and cut their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.